When does entresto become generic?

As of now, Entresto (sacubitril/valsartan) is not generic in the U.S. or most other markets.

- In the United States, generic entry depends on patent and data exclusivity timelines. The main patents protecting sacubitril/valsartan are expected to expire around 2031–2032, with possible additional delay due to pediatric exclusivity or later patents. This means generic versions would be unlikely before the early-to-mid 2030s, at the earliest, assuming no patent challenges or settlements that would allow earlier entry.
- Global dates vary by country depending on local patents and regulatory decisions.

How to check current status:
- Look up the FDA FDA Orange Book entry for Entresto (sacubitril/valsartan) to see current patent and exclusivity status and their expiration dates.
- If you’re in a different country, check your national drug regulatory authority or the local Orange Book-equivalent listing for patent and exclusivity information.

If you’d like, tell me your country and I can look up the latest status there.